Research Papers:

Storkhead box 2 and melanoma inhibitory activity promote oral squamous cell carcinoma progression

Tomonori Sasahira _, Yukiko Nishiguchi, Rina Fujiwara, Miyako Kurihara, Tadaaki Kirita, Anja Katrin Bosserhoff and Hiroki Kuniyasu

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:26751-26764. https://doi.org/10.18632/oncotarget.8495

Metrics: PDF 1223 views  |   HTML 2282 views  |   ?  


Tomonori Sasahira1, Yukiko Nishiguchi1, Rina Fujiwara1, Miyako Kurihara1,2, Tadaaki Kirita2, Anja Katrin Bosserhoff3, Hiroki Kuniyasu1

1Department of Molecular Pathology, Nara Medical University, Kashihara, Japan

2Department of Oral and Maxillofacial Surgery, Nara Medical University, Kashihara, Japan

3Institute of Biochemistry, Friedrich-Alexander University of Erlangen-Nürnberg, Erlangen, Germany

Correspondence to:

Tomonori Sasahira, email: [email protected]

Keywords: STOX2, MIA, metastasis, multidrug resistance, oral cancer

Received: December 15, 2015    Accepted: March 10, 2016    Published: March 30, 2016


Background: Storkhead box protein 2 (STOX2) is a transcriptional factor associated with pre-eclampsia with fetal growth restriction. We recently reported that melanoma inhibitory activity (MIA) promotes oral squamous cell carcinoma (OSCC) progression. However, the relationship between STOX2 and MIA remains unknown in malignancies.

Methods: We used immunohistochemistry and PCR to investigate MIA and STOX2 expression in OSCC. We also performed functional analysis in human OSCC cells.

Results: MIA and STOX2 mRNA levels were higher in OSCCs than in normal oral epithelial cells, and upregulation of STOX2 was significantly correlated with overexpression of MIA. Immunostaining for STOX2 was associated with nodal metastasis (P = 0.0002) and MIA expression (P < 0.0001). Furthermore, MIA expression (P = 0.0035) and STOX2 expression (P = 0.0061) were associated with poor outcome in OSCCs. In vitro analysis using OSCC cells revealed that MIA increased expression of STOX2 by paracrine manner. Moreover, STOX2 accelerated OSCC cell growth, invasion, suppressed apoptosis, and enhanced resistance to paclitaxel, cisplatin, and 5-FU.

Conclusions: Our results suggest that MIA-STOX2 signaling may be a useful diagnostic and therapeutic target in OSCCs.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8495